Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Mereo BioPharma clinical trials
The registry lists 40 studies whose lead sponsor is Mereo BioPharma or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 17, 2025.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Mereo BioPharma.
- OncoMed Pharmaceuticals, Inc.28 studies →Acquired — became part of Mereo BioPharma, Apr 23, 2019 · source ↗
Something wrong?
- Mereo BioPharma12 studiesSame company
Something wrong?
Focus areas
Conditions Mereo BioPharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 40 of 40.
- A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT04761198Phase 1/2
- A 6 Month Safety Extension Study of MBGS205CompletedNCT02908074Phase 2
- Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an ExacerbationCompletedNCT01332097Phase 2
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic CancerCompletedNCT01647828Phase 1/2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic HypogonadismCompletedNCT02730169Phase 2
- A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.CompletedNCT03636347Phase 2
- Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseCompletedNCT02700919Phase 2
- A Safety & Efficacy Study of BGS649 in Women With Refractory EndometriosisTerminatedNCT01116440Phase 2
- Safety & Efficacy of BCT197 in Patients Undergoing Cardiac SurgeryTerminatedNCT01336959Phase 2
- BGS649 Monotherapy in Moderate to Severe Endometriosis PatientsCompletedNCT01190475Phase 2
- Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal MenTerminatedNCT01200862Phase 2
- Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT02289898Phase 2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid TumorsCompletedNCT00744562Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung CancerCompletedNCT02259582Phase 2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01189929Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-59R5 in Subjects With Solid TumorsCompletedNCT01277146Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-18R5 in Subjects With Solid TumorsCompletedNCT01345201Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid MalignanciesCompletedNCT01703572Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung CancerCompletedNCT01189968Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum TherapyTerminatedNCT01859741Phase 1/2
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant OvarianTerminatedNCT01952249Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal CancerCompletedNCT01189942Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast CancerCompletedNCT01973309Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLCCompletedNCT01957007Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic CancerCompletedNCT02005315Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic CancerCompletedNCT02050178Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube CancerCompletedNCT03030287Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian CancerCompletedNCT02092363Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal CancerCompletedNCT03031691Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-54F28 in Subjects With Solid TumorsCompletedNCT01608867Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid TumorsCompletedNCT01778439Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10CompletedNCT02482441Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic TumorsTerminatedNCT03295942Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1 Study of OMP-305B83 in Subjects With Solid TumorsCompletedNCT02298387Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular CancerCompletedNCT02069145Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCompletedNCT02722954Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of OMP-305B83 in Subjects With Metastatic Colorectal CancerTerminatedNCT03035253Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03119428Phase 1
Sponsor listed in the registry: OncoMed Pharmaceuticals, Inc. · First submitted before OncoMed Pharmaceuticals, Inc. became part of Mereo BioPharma
- The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsCompletedNCT03498170Phase 1
- The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersCompletedNCT02926326Phase 1